Fourth Quarter & Full Year 2022 Financial & Business Update
ADCETRIS Blockbuster Sales Potential Driven by 1L cHL OS Benefit
and Recent Pediatric Label Expansion
ECHELON-1 OS data¹ resulted in NCCN guidelines update
to category 1, preferred regimen² and submitted to FDA
Probability of Overall Survival
1.0-
0.9-
0.8-
0.7-
0.6-
0.5-
0.4-
0.3-
0.2-
A+AVD
ABVD
Hazard ratio for death, 0.59
(95% CI, 0.40-0.88)
P-0.000 by log-rank test
0.1-
0.0+
T
0 6 12 18 24
30 36 42 48 54 60 66 72 78
Months since Randomization
84
90 96 102
No. at Risk
A+AVD
ABVD
664 638 626 612 598 584 572 557 538 517 494 461 350 209 97 27 4 0
670 634 614 604 587 567 545 527 505 479 454 411 308 191 84 11
1
0
Phase 2 AN+AD 1L CHL data presented at ASH
• Demonstrated 92% CR rate and 95% ORR in Stage I/II 1L patients
•
95% Stage III/IV patients progression free at 17 months median follow-up
Seagen Collaboration with Takeda
ADCETRIS
brentuximab vedotin | for injection
Currently foundation of
care in multiple CD30-
expressing lymphomas
Pediatric label granted by FDA in high-risk 1L CHL
based on positive EFS data presented at ASCO³ and
now NCCN category 1 preferred regimen
Event free survival (EFS)
0.8
0.6-
0.4-
02-
BV-AVE-PC 92.1% (95% CI, 88.4, 94.7)
ABVE-PC 82.5% (95% CI 77.4, 86.5)
HR 0.41 [CI 0.25, 0.67] p=0.0002
0.0
Years 0
1
2
ABVE-PC 289
BV-AVEPC 298
246
275
226
260
3
164
194
5
112
105
45
45
3
Studies ongoing in DLBCL and solid tumors
⚫ ECHELON-3 DLBCL enrollment ongoing
Initial data in solid tumors expected in 1H 2023
1 Ansell, et al, New England Journal of Medicine 2022; 2 NCCN guidelines updated to include ADCETRIS + AVD as a Preferred regimen with Category 1 level of evidence;
3 Castellino, et al, ASCO 2022 Abstract 7504; 4 NCCN guidelines updated to include BV-AVE-PC as a Preferred Regimen with Category 1 level of evidence; refer to
ADCETRIS USPI for complete safety information, including a BOXED WARNING for Progressive Multifocal Leukoencephalopathy (PML): JC virus infection
resulting in PML and death can occur in ADCETRIS-treated patients
22
22View entire presentation